Matthew Pattillo, MD
Pulmonary Disease · Dallas, TXNPI 1295994770
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 66.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $5,300 and has fallen 75.6% since, to $1,291 in 2025.
Across 170 payments — averaging $124.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$14K
- Boehringer Ingelheim$3K
- AstraZeneca$774
- Sanofi$667
- Actelion Pharmaceuticals US, Inc.$633
- GSK$459
- plus $1K from 19 others
What the payments were for
- Consulting fees$1171%
- Speaking & faculty fees$11,03052%
- Travel & lodging$2,02210%
- Food & beverage$4,44821%
- Education$3,32716%
- Gifts$1371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 28 | $14,049 |
| Boehringer Ingelheim | 7 | $3,147 |
| AstraZeneca(2 entities) | 25 | $774 |
| Sanofi | 27 | $667 |
| Actelion Pharmaceuticals US, Inc. | 14 | $633 |
| GSK | 24 | $459 |
| Regeneron Healthcare Solutions, Inc. | 7 | $295 |
| Inari Medical, Inc. | 2 | $208 |
| Amgen | 4 | $149 |
| Sanofi-aventis U.S. LLC | 2 | $146 |
| Edwards Lifesciences | 1 | $107 |
| Mylan Specialty L.p. | 4 | $67 |
| Pfizer | 4 | $62 |
| Novartis | 3 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Grifols USA, LLC | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 3 | $32 |
| Circassia Inc. | 2 | $28 |
| Electromed, Inc. | 2 | $27 |
| United Therapeutics Corporation | 1 | $21 |
| Verona Pharma, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Insmed, Inc. | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,359
- DA VINCI SP$4,150
- FLOWTRIEVER CATHETER, S$156
- CT THROMBECTOMY SYSTEM KIT$156
- DUPIXENT$124
- NUCALA$124
- FASENRA$124
- UPTRAVI$111
- OPSUMIT$111
- HemoSphere$107
How this compares
$21,082 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 19 | $244,300 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 263 | $209,906 |
| AdempasRiociguat | 14 | $193,978 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $131,998 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 133 | $113,288 |
| Dupixent PenDupilumab | 13 | $46,930 |
| Dupixent SyringeDupilumab | 13 | $42,946 |
| Spiriva RespimatTiotropium Bromide | 38 | $35,329 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $34,479 |
| EliquisApixaban | 35 | $33,795 |
| Tadalafil | 13 | $29,350 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $17,270 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $15,856 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $13,577 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $6,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $459 | $267,623370 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $633 | $244,30019 claims |
| Grifols USA, LLCProlastin C | $36 | $131,99812 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $774 | $126,865190 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $3,147 | $51,18568 claims |
| PfizerEliquis | $62 | $33,79535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Dallas
- Yolanda MagetoDallas$239K
- Mark MillardDallas$192K
- Raksha JainDallas$153K
- Sonja BartolomeDallas$75K
- Kelly ChinDallas$72K
- Fernando TorresDallas$61K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.